Search Results
4 results for search term 'AAV' in category Project
Evolving High Potency AAV Vectors for Neuromuscular Genome EditingProject [Delivery Systems]Show Experiments (7)
|
SCGE AAV Tropism Supplement: Evaluation Across Multiple Tissues in MiceProject [AAV tropism]Show Experiments (1) |
Novel AAVs Engineered for Efficient and Noninvasive Cross-Species Gene Editing Throughout the Central Nervous SystemProject [Delivery Systems] |
Vascularized kidney organoids on chip for efficacy and toxicity testing of somatic genome editingProject [Biological Effects]Show Experiments (7)
|
4 results for search term 'AAV' in category Project
Type | Subtype | Name | Description | Source | Last Updated Date | View Associated... |
---|---|---|---|---|---|---|
Evolving High Potency AAV Vectors for Neuromuscular Genome Editing | Recombinant adeno-associated viruses (AAV) have emerged as safe and effective vectors for clinical gene therapy applications including systemic treatment of neuromuscular diseases such as Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), and Giant Axonal Neuropathy (GAN) amongst others. However, genome editing in neuromuscular tissue, in particular, is challenging. The current proposal is on a comprehensive and innovative approach to evolve high potency AAV variants for systemic neuromuscular genome editing. | 2020-11-19 |
Show Experiments (7)
|
|||
SCGE AAV Tropism Supplement: Evaluation Across Multiple Tissues in Mice | 2023-02-10 |
Show Experiments (1) |
||||
Novel AAVs Engineered for Efficient and Noninvasive Cross-Species Gene Editing Throughout the Central Nervous System | This project aims to advance the NIH Somatic Cell Genome Editing Program’s objective to identify novel delivery technologies that enable genome editing in therapeutically relevant somatic cell populations. We will use proven virus engineering methods to develop new vehicles that can deliver genome editing machinery throughout the adult mammalian central nervous system. Accomplishing this objective would pave the road for applying gene editing, and gene therapy more broadly, to the study and treatment of neurological and psychiatric disorders. | 2021-04-17 | ||||
Vascularized kidney organoids on chip for efficacy and toxicity testing of somatic genome editing | The proposed work will take advantage of the state-of-the-art technology of kidney organoids that we recently generated from human pluripotent stem cells (hPSCs) and further advance this technology toward the goal of establishing kidney tissue platforms for assessment of somatic genome editing. We will optimize kidney organoid generation and AAV transduction for assessment of adverse effects of CRISR genome editing. Further, we will incorporate the 3D-printed vascular system into kidney organoids to simulate in vivo pharmacokinetics and pharmacodynamics on chips. | 2023-09-22 |
Show Experiments (7)
|